Demethylzeylasteral targets lactate by inhibiting histone lactylation to suppress the tumorigenicity of liver cancer stem cells

• Published in: Pharmacological Research
• Main Authors: Lianhong Pan, Fan Feng, Jiaqin Wu, Shibing Fan, Juanjuan Han, Shunxi Wang, Li Yang, Wanqian Liu, Chunli Wang, Kang Xu
• Format: Article in Journal/Newspaper
• Language: English
• Published: Elsevier 2022
• Subjects: Liver cancer; Glycolysis; Lactate; Histone lactylation; Tumorigenicity; Therapeutics. Pharmacology; RM1-950; DML
• Online Access: https://doi.org/10.1016/j.phrs.2022.106270; https://doaj.org/article/5ad032f5e0db4e629f79130e42308e00

Cancer stem cells drive tumor initiation, progression, and recurrence, which compromise the effectiveness of anti-tumor drugs. Here, we report that demethylzeylasteral (DML), a triterpene anti-tumor compound, suppressed tumorigenesis of liver cancer stem cells (LCSCs) by interfering with lactylation of a metabolic stress-related histone. Using RNA sequencing (RNA-seq) and gas chromatography-mass spectrometric (GC-MS) analysis, we showed that the glycolysis metabolic pathway contributed to the anti-tumor effects of DML, and then focused on lactate downstream regulation as the molecular target. Mechanistically, DML opposed the progress of hepatocellular carcinoma (HCC), which was efficiently facilitated by the increase in H3 histone lactylation. Two histone modification sites: H3K9la and H3K56la, which were found to promote tumorigenesis, were inhibited by DML. In addition, we used a nude mouse tumor xenograft model to confirm that the anti-liver cancer effects of DML are mediated by regulating H3 lactylation in vivo. Our findings demonstrate that DML suppresses the tumorigenicity induced by LCSCs by inhibiting H3 histone lactylation, thus implicating DML as a potential candidate for the supplementary treatment of hepatocellular carcinoma.